CDK4 and breast carcinoma: Therefore, in this study, we examined the antitumor effects of the CDK4/6 inhibitor abemaciclib and ABT‐263 using MDA‐MB‐231 and MCF‐7 human breast cancer cell lines and investigated the underlying mechanisms.